NDAORALCAPSULEPriority Review
Approved
Aug 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
CYSTAGON (cysteamine bitartrate) by Viatris (2) is mechanism of action cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is abnormal; in the nephropathic form, accumulation of cystine and formation of crystals damage various organs, especially the kidney, leading to renal tubular fanconi syndrome and progressive glomerular failure, with end stage renal failure by the end of the first decade of life. First approved in 1994.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTAGON (cysteamine bitartrate) is an oral aminothiol approved in 1994 for nephropathic cystinosis, a rare autosomal recessive lysosomal storage disorder. It works by participating in thiol-disulfide interchange reactions within lysosomes to convert cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome. The drug prevents cystine crystal accumulation and delays progressive organ damage, particularly renal failure, growth failure, rickets, and photophobia.
$0.075MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D claims (141 in 2023), indicating a niche rare disease market with limited team expansion opportunities.
Mechanism of Action
Mechanism of Action Cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is abnormal; in the nephropathic form, accumulation of cystine and formation of crystals damage various organs, especially the kidney, leading to renal tubular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
PK and PD Study of NPI-001 and Cysteamine Bitartrate
Started Oct 2023
12 enrolled
Cystinosis
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
Started May 2015
22 enrolled
Mitochondrial Diseases
Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
Started Jan 2013
41 enrolled
Cystinosis
Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
Started Dec 2012
17 enrolled
Cystinosis
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Started Aug 2010
60 enrolled
Cystinosis
Worked on CYSTAGON at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.